Free Trial

InspireMD Q3 2024 Earnings Report

InspireMD logo
$2.94 +0.22 (+8.09%)
As of 03:57 PM Eastern

InspireMD EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.15

InspireMD Revenue Results

Actual Revenue
$1.81 million
Expected Revenue
$1.74 million
Beat/Miss
Beat by +$70.00 thousand
YoY Revenue Growth
N/A

InspireMD Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

InspireMD Earnings Headlines

This red-hot crypto opportunity could slam shut soon
The situation is clear: Crypto is a HUGE hit with investors. Bitcoin became so outrageously popular that early adopters had a shot at absolutely outrageous 14,510% gains or more over the last decade. And it’s far from the only time traders had a shot at obscene gains on crypto. With Ethereum, lucky traders who put $1,000 in 5 years ago and held through the ups and downs would have seen it turn into a staggering $709,740. And now there is a NEW blockchain seeing rapid adoption…
InspireMD Finance Chief Craig Shore To Retire
See More InspireMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InspireMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InspireMD and other key companies, straight to your email.

About InspireMD

InspireMD (NYSE:NSPR), a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

View InspireMD Profile

More Earnings Resources from MarketBeat